Health & Fitness
Health and Fitness
Health and Fitness 
Fri, January 9, 2009
Thu, January 8, 2009
Expression Analysis (EA) Purchases Its First Illumina Genome Analyzer
SAN DIEGO--([ BUSINESS WIRE ])--Illumina (NASDAQ:ILMN) today announced that Expression Analysis, an Illumina certified service provider (CSPro) and leading supplier of genotyping, gene expression, and resequencing services for genetic research, purchased its first Genome Analyzer. With this purchase, Expression Analysis becomes the only CSPro that owns all four of Illumina's genomic research platforms: Genome Analyzer, iScan, BeadStation, and BeadXpress. This means that customers can perform truly integrated genetic analysis studies, from whole-genome to targeted screening.
"We continue to invest in Illumina's technology because of the significant client demand for their genomic research platforms," said Steve McPhail, President and CEO of Expression Analysis. "At next week's Plant and Animal Genome Conference we will launch our new agricultural genomics services offering. The Genome Analyzer plays a critical role in this program because of its ability to offer a broad range of sequencing applications to support comprehensive DNA, gene expression and regulation, and epigenomics-based studies, for this market segment."
"In addition to owning at least one of every platform marketed by Illumina, we're excited to know that Expression Analysis opted to purchase their first Genome Analyzer in order to expand sequencing service offerings, based on client demand. Greater access to next-generation sequencing approaches in mainstream life sciences will help accelerate the overall pace of discovery and enable greater freedom for researchers to go where the biology takes them in their studies," said Tristan Orpin, Senior Vice President of Commercial Operations at Illumina.
About Illumina
Illumina ([ www.illumina.com ]) is a leading developer, manufacturer, and marketer of next-generation life-science tools and integrated systems for the analysis of genetic variation and biological function. Using our proprietary technologies, we provide a comprehensive line of products and services that currently serve the sequencing, genotyping, and gene expression markets, and we expect to enter the market for molecular diagnostics. Our customers include leading genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, and biotechnology companies. Our tools provide researchers around the world with the performance, throughput, cost effectiveness, and flexibility necessary to perform the billions of genetic tests needed to extract valuable medical information from advances in genomics and proteomics. We believe this information will enable researchers to correlate genetic variation and biological function, which will enhance drug discovery and clinical research, allow diseases to be detected earlier, and permit better choices of drugs for individual patients.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: this release may contain forward-looking statements that involve risks and uncertainties. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are Illumina's ability (i) to develop and commercialize further our BeadArray™, VeraCode®, and Solexa® technologies and to deploy new sequencing, gene expression, and genotyping products and applications for our technology platforms, (ii) to manufacture robust instrumentation and reagents technology, together with other factors detailed in our filings with the Securities and Exchange Commission including our recent filings on Forms 10-K and 10-Q or in information disclosed in public conference calls, the date and time of which are released beforehand. We disclaim any intent or obligation to update these forward-looking statements beyond the date of this release.